Amphastar Pharmaceuticals, Inc. (AMPH)
NASDAQ: AMPH · Real-Time Price · USD
29.37
+0.50 (1.73%)
At close: Nov 13, 2026, 4:00 PM EST
29.90
+0.53 (1.80%)
After-hours: Nov 13, 2026, 5:31 PM EST
Amphastar Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 745.79 | 719.89 | 712.81 | 593.24 | 498.99 | 437.77 |
Other Revenue | - | - | 19.15 | 51.16 | - | - |
| 745.79 | 719.89 | 731.97 | 644.4 | 498.99 | 437.77 | |
Revenue Growth | 3.11% | -1.65% | 13.59% | 29.14% | 13.98% | 25.13% |
Cost of Revenue | 396.7 | 363.83 | 358.11 | 293.27 | 250.13 | 238.03 |
Gross Profit | 349.09 | 356.06 | 373.86 | 351.12 | 248.86 | 199.74 |
Selling, General & Admin | 117.06 | 106.71 | 94.52 | 80.39 | 66.59 | 67.12 |
Research & Development | 92.29 | 85.84 | 73.91 | 73.74 | 74.77 | 60.93 |
Operating Expenses | 209.35 | 192.55 | 168.44 | 154.13 | 141.36 | 128.05 |
Operating Income | 139.74 | 163.5 | 205.42 | 196.99 | 107.5 | 71.69 |
Interest Expense | -19.2 | -29.78 | -35.34 | -33.06 | -1.85 | -0.89 |
Interest & Investment Income | 9.4 | 8.68 | 10.61 | 5.46 | 1.32 | 0.6 |
Earnings From Equity Investments | - | - | -0.57 | -1.98 | -1.18 | -0.21 |
Other Non Operating Income (Expenses) | -0.36 | 4.32 | 9.08 | 1.97 | 9.07 | 13.54 |
EBT Excluding Unusual Items | 129.57 | 146.72 | 189.19 | 169.38 | 114.86 | 84.73 |
Legal Settlements | - | -23.1 | - | - | - | 1 |
Other Unusual Items | - | - | - | - | - | -1.8 |
Pretax Income | 129.57 | 123.62 | 189.19 | 169.38 | 114.86 | 83.93 |
Income Tax Expense | 30.61 | 25.53 | 29.67 | 31.83 | 23.48 | 20.63 |
Earnings From Continuing Operations | 98.96 | 98.09 | 159.52 | 137.55 | 91.39 | 63.3 |
Minority Interest in Earnings | - | - | - | - | - | -1.19 |
Net Income | 98.96 | 98.09 | 159.52 | 137.55 | 91.39 | 62.12 |
Net Income to Common | 98.96 | 98.09 | 159.52 | 137.55 | 91.39 | 62.12 |
Net Income Growth | -11.35% | -38.51% | 15.98% | 50.51% | 47.12% | 4327.37% |
Shares Outstanding (Basic) | 44 | 47 | 48 | 48 | 49 | 48 |
Shares Outstanding (Diluted) | 45 | 48 | 52 | 53 | 52 | 50 |
Shares Change | -8.01% | -7.38% | -1.78% | 1.09% | 5.31% | 1.34% |
EPS (Basic) | 2.23 | 2.10 | 3.29 | 2.85 | 1.88 | 1.30 |
EPS (Diluted) | 2.18 | 2.03 | 3.06 | 2.60 | 1.74 | 1.25 |
EPS Growth | -4.01% | -33.66% | 17.69% | 49.43% | 39.20% | 4090.97% |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | 139.02 | 121.23 | 172.35 | 145.34 | 65.15 | 70.54 |
Free Cash Flow Per Share | 3.07 | 2.51 | 3.31 | 2.74 | 1.24 | 1.42 |
Gross Margin | 46.81% | 49.46% | 51.08% | 54.49% | 49.87% | 45.63% |
Operating Margin | 18.74% | 22.71% | 28.06% | 30.57% | 21.54% | 16.38% |
Profit Margin | 13.27% | 13.63% | 21.79% | 21.34% | 18.31% | 14.19% |
Free Cash Flow Margin | 18.64% | 16.84% | 23.54% | 22.55% | 13.06% | 16.11% |
EBITDA | 198.32 | 220.2 | 258.39 | 235.02 | 132.27 | 94.95 |
EBITDA Margin | 26.59% | 30.59% | 35.30% | 36.47% | 26.51% | 21.69% |
D&A For EBITDA | 58.58 | 56.7 | 52.97 | 38.04 | 24.77 | 23.27 |
EBIT | 139.74 | 163.5 | 205.42 | 196.99 | 107.5 | 71.69 |
EBIT Margin | 18.74% | 22.71% | 28.06% | 30.57% | 21.54% | 16.38% |
Effective Tax Rate | 23.63% | 20.65% | 15.68% | 18.79% | 20.44% | 24.58% |
Revenue as Reported | 719.89 | 719.89 | 731.97 | 644.4 | 498.99 | 437.77 |
Advertising Expenses | - | 10.2 | 10.5 | 10.4 | 8.7 | 8.1 |